Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Antonia, S.; Rizvi, N.; Brahmer, J.; Ou, S. H.; Khleif, S. N.; Hwu, W. J.; Gutierrez, M.; Schoffski, P.; Hamid, O.; Weiss, J.; Lutzky, J.; Maio, M.; Nemunaitis, J.; Jaeger, D.; Balmanoukian, A.; Rebelatto, M. C.; Steele, K. E.; Jin, X. P.; Robbins, P. B.; Blake-Haskins, J. A.; Segal, N. H. |
| Abstract Title: | Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) |
| Meeting Title: | CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival |
| Journal Title: | Cancer Immunology Research |
| Volume: | 4 |
| Issue: | Suppl. |
| Meeting Dates: | 2015 Sep 16-19 |
| Meeting Location: | New York, NY |
| ISSN: | 2326-6066 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-01-01 |
| Language: | English |
| ACCESSION: | WOS:000375484400034 |
| DOI: | 10.1158/2326-6074.cricimteatiaacr15-a047 |
| PROVIDER: | wos |
| PUBMED: | 27119139 |
| Notes: | Meeting Abstract: A047 -- Source: Wos |
